Lifevantage (LFVN)


Market Price (8/31/2026): $6.26 | Market Cap: $78.1 MilSector: Consumer Staples | Industry: Packaged Foods & Meats

Lifevantage (LFVN)


Market Price (8/31/2026): $6.26
Market Cap: $78.1 Mil
Sector: Consumer Staples
Industry: Packaged Foods & Meats

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.3%, Dividend Yield is 3.0%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.9%, FCF Yield is 8.4%

Megatrend and thematic drivers
Megatrends include Health & Wellness Trends, and E-commerce & DTC Adoption. Themes include Nutritional Supplements, Functional Foods & Beverages, Show more.

Weak multi-year price returns
2Y Excs Rtn is -60%, 3Y Excs Rtn is -23%

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -20%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -4.0%, Rev Chg QQuarterly Revenue Change % is -23%

Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 56%

Significant short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 21.15

Key risks
LFVN key risks include [1] operational and reputational challenges from its direct selling model and [2] a high revenue dependence on a limited number of key products.

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.3%, Dividend Yield is 3.0%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.9%, FCF Yield is 8.4%
1 Megatrend and thematic drivers
Megatrends include Health & Wellness Trends, and E-commerce & DTC Adoption. Themes include Nutritional Supplements, Functional Foods & Beverages, Show more.
2 Weak multi-year price returns
2Y Excs Rtn is -60%, 3Y Excs Rtn is -23%
3 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -20%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -4.0%, Rev Chg QQuarterly Revenue Change % is -23%
4 Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 56%
5 Significant short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 21.15
6 Key risks
LFVN key risks include [1] operational and reputational challenges from its direct selling model and [2] a high revenue dependence on a limited number of key products.

LFVN in ETFs

Weight = LFVN's share of each fund

VTI0.00%
AVUV0.00%
DFAS0.00%
DFAC0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 8/27/2026

Lifevantage (LFVN) stock has gained about 25% since 4/30/2026 because of the following key factors:

1. Leadership Transition with New CEO Appointment. LifeVantage announced the appointment of Terrence Moorehead as Chief Executive Officer, effective August 5, 2026. This leadership change followed the retirement of Steve Fife on April 30, 2026, with Michael Beindorff serving as interim CEO. The arrival of a new CEO often signals a fresh strategic direction and can generate investor optimism for future growth and operational improvements.

2. Product Innovation and Patent Grant. The company highlighted product innovation, including the granting of a U.S. patent for its Healthy Glow Essentials Stack, which was announced at the Momentum Academy on April 20, 2026. This news was met with a positive market reaction, with the stock gaining 7.32% in the session following the announcement. Such advancements in its nutrigenomics product portfolio can be seen by investors as a driver for future revenue.

Show more
Updated on 8/27/2026

Lifevantage (LFVN) stock has gained about 25% since 4/30/2026 because of the following key factors:

1. Leadership Transition with New CEO Appointment. LifeVantage announced the appointment of Terrence Moorehead as Chief Executive Officer, effective August 5, 2026. This leadership change followed the retirement of Steve Fife on April 30, 2026, with Michael Beindorff serving as interim CEO. The arrival of a new CEO often signals a fresh strategic direction and can generate investor optimism for future growth and operational improvements.

2. Product Innovation and Patent Grant. The company highlighted product innovation, including the granting of a U.S. patent for its Healthy Glow Essentials Stack, which was announced at the Momentum Academy on April 20, 2026. This news was met with a positive market reaction, with the stock gaining 7.32% in the session following the announcement. Such advancements in its nutrigenomics product portfolio can be seen by investors as a driver for future revenue.

3. Consistent Quarterly Dividend Declarations. LifeVantage continued to declare regular quarterly cash dividends, with the most recent being $0.05 per share announced on August 21, 2026. The commitment to returning capital to shareholders through dividends, despite a challenging financial environment with declining revenue in fiscal Q3 and Q4 2026, can maintain investor confidence and attract income-focused investors.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 26.6% change in LFVN stock from 4/30/2026 to 8/30/2026 was primarily driven by a 93.6% change in the company's P/E Multiple.
(LTM values as of)43020268302026Change
Stock Price ($)5.026.3626.6%
Change Contribution By: 
Total Revenues ($ Mil)210183-13.1%
Net Income Margin (%)3.7%2.8%-25.8%
P/E Multiple8.115.693.6%
Shares Outstanding (Mil)13121.4%
Cumulative Contribution26.6%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 8/30/2026
ReturnCorrelation
LFVN26.6% 
Market (SPY)7.1%1.7%
Sector (XLP)1.4%-2.3%

Fundamental Drivers

The 21.9% change in LFVN stock from 1/31/2026 to 8/30/2026 was primarily driven by a 144.9% change in the company's P/E Multiple.
(LTM values as of)13120268302026Change
Stock Price ($)5.226.3621.9%
Change Contribution By: 
Total Revenues ($ Mil)229183-20.2%
Net Income Margin (%)4.4%2.8%-37.3%
P/E Multiple6.415.6144.9%
Shares Outstanding (Mil)1212-0.6%
Cumulative Contribution21.9%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2026 to 8/30/2026
ReturnCorrelation
LFVN21.9% 
Market (SPY)11.5%9.3%
Sector (XLP)2.9%0.1%

Fundamental Drivers

The -48.0% change in LFVN stock from 7/31/2025 to 8/30/2026 was primarily driven by a -32.5% change in the company's Net Income Margin (%).
(LTM values as of)73120258302026Change
Stock Price ($)12.226.36-48.0%
Change Contribution By: 
Total Revenues ($ Mil)222183-17.9%
Net Income Margin (%)4.1%2.8%-32.5%
P/E Multiple16.515.6-5.3%
Shares Outstanding (Mil)1212-1.0%
Cumulative Contribution-48.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2025 to 8/30/2026
ReturnCorrelation
LFVN-48.0% 
Market (SPY)22.7%13.9%
Sector (XLP)9.3%4.5%

Fundamental Drivers

The 40.9% change in LFVN stock from 7/31/2023 to 8/30/2026 was primarily driven by a 60.3% change in the company's P/S Multiple.
(LTM values as of)73120238302026Change
Stock Price ($)4.516.3640.9%
Change Contribution By: 
Total Revenues ($ Mil)210183-13.1%
P/S Multiple0.30.460.3%
Shares Outstanding (Mil)13121.2%
Cumulative Contribution40.9%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2023 to 8/30/2026
ReturnCorrelation
LFVN40.9% 
Market (SPY)74.0%16.8%
Sector (XLP)21.5%6.2%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
LFVN Return-32%-40%75%197%-64%6%-19%
Peers Return10%-44%4%-48%20%-21%-69%
S&P 500 Return27%-19%24%23%16%13%106%

Monthly Win Rates [3]
LFVN Win Rate25%33%42%67%33%50% 
Peers Win Rate60%30%50%37%40%45% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
LFVN Max Drawdown-40%-47%-47%-31%-76%-44% 
Peers Max Drawdown-33%-55%-43%-57%-36%-45% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: HLF, NUS, USNA, MED, NATR. See LFVN Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/28/2026 (YTD)

How Low Can It Go

EventLFVNS&P 500
2023 SVB Regional Banking Crisis
  % Loss-21.2%-6.7%
  % Gain to Breakeven27.0%7.1%
  Time to Breakeven6 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-47.1%-24.5%
  % Gain to Breakeven89.1%32.4%
  Time to Breakeven338 days427 days
2020 COVID-19 Crash
  % Loss-49.4%-33.7%
  % Gain to Breakeven97.5%50.9%
  Time to Breakeven43 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-11.1%-19.2%
  % Gain to Breakeven12.4%23.8%
  Time to Breakeven19 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-63.8%-3.7%
  % Gain to Breakeven175.9%3.9%
  Time to Breakeven414 days6 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-11.4%-12.2%
  % Gain to Breakeven12.8%13.9%
  Time to Breakeven4 days62 days

Compare to HLF, NUS, USNA, MED, NATR

In The Past

Lifevantage's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventLFVNS&P 500
2023 SVB Regional Banking Crisis
  % Loss-21.2%-6.7%
  % Gain to Breakeven27.0%7.1%
  Time to Breakeven6 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-47.1%-24.5%
  % Gain to Breakeven89.1%32.4%
  Time to Breakeven338 days427 days
2020 COVID-19 Crash
  % Loss-49.4%-33.7%
  % Gain to Breakeven97.5%50.9%
  Time to Breakeven43 days140 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-63.8%-3.7%
  % Gain to Breakeven175.9%3.9%
  Time to Breakeven414 days6 days
2014-2016 Oil Price Collapse
  % Loss-61.4%-6.8%
  % Gain to Breakeven159.2%7.3%
  Time to Breakeven185 days15 days
2013 Taper Tantrum
  % Loss-46.1%-0.2%
  % Gain to Breakeven85.4%0.2%
  Time to Breakeven1818 days1 days
2010 Eurozone Sovereign Debt Crisis / Flash Crash
  % Loss-28.8%-15.4%
  % Gain to Breakeven40.5%18.2%
  Time to Breakeven9 days125 days
2008-2009 Global Financial Crisis
  % Loss-68.2%-53.4%
  % Gain to Breakeven214.3%114.4%
  Time to Breakeven61 days1085 days

Compare to HLF, NUS, USNA, MED, NATR

In The Past

Lifevantage's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Lifevantage (LFVN)

```html

LifeVantage Corporation (LFVN) is a health and wellness company specializing in the research, development, and distribution of nutrigenomic products. These products are designed to activate the body's natural health processes. The company focuses on formulating and selling a diverse portfolio that includes dietary supplements, nootropics, pre- and probiotics, and weight management solutions, alongside a range of personal care items.

The core of LifeVantage's product offerings includes the Protandim line, which features scientifically validated dietary supplements known as nutrigenomic activators. Other key products include LifeVantage Omega+ and ProBio for general health, Petandim for Dogs, and Axio energy drink mixes. In addition to internal health products, the company provides an extensive line of anti-aging skin care, hair care, and bath and body products under its TrueScience brand, as well as targeted relief products. Its weight management solutions are marketed under the PhysIQ brand.

LifeVantage distributes its products internationally, leveraging a multi-channel sales strategy that combines its company website with a broad network of independent distributors. The company maintains a significant global footprint, serving markets across North America (including the U.S., Mexico, and Canada), Asia-Pacific (such as Japan, Australia, Hong Kong, Thailand, Taiwan, New Zealand, Singapore, and China), and Europe (including the UK, Netherlands, Germany, Austria, Spain, Ireland, and Belgium).

```

AI Analysis | Feedback

Here are 1-3 brief analogies for Lifevantage (LFVN):

  • Like a Herbalife focused on advanced anti-aging and nutrigenomic products.
  • A direct-selling version of The Vitamin Shoppe, but also with beauty and personal care lines.

AI Analysis | Feedback

  • Protandim: A line of scientifically validated dietary supplements.
  • LifeVantage Omega+: A dietary supplement combining DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3.
  • LifeVantage ProBio: A dietary supplement designed to support digestive system health.
  • PhysIQ: A brand offering a line of weight management products.
  • Petandim for Dogs: A supplement specifically formulated to combat oxidative stress in dogs.
  • Axio: A line of energy drink mixes.
  • LifeVantage TrueScience (Skincare): Anti-aging skin care products including cleansers, lotions, serums, and creams.
  • LifeVantage TrueScience (Haircare): Hair care products such as invigorating shampoos, nourishing conditioners, and scalp serums.
  • LifeVantage TrueScience (Bath and Body & Targeted Relief): Products encompassing body lotions, washes, butters, deodorants, soothing balms, and body rubs.

AI Analysis | Feedback

LifeVantage Corporation (LFVN) sells its products primarily to individuals through its website and a network of independent distributors. Based on its diverse product offerings, the company serves the following categories of customers:

  • Health & Wellness Enthusiasts: This category includes individuals seeking dietary supplements, nutrigenomic activators (such as Protandim), pre- and pro-biotics, and weight management products to support overall health, vitality, and anti-aging.
  • Beauty & Personal Care Consumers: This group comprises individuals interested in anti-aging skincare, hair care products (shampoos, conditioners, scalp serums), and general bath and body products (lotions, washes, deodorants).
  • Performance & Cognitive Support Users: This segment targets individuals looking for products like nootropics and energy drink mixes (Axio) to enhance cognitive function, improve energy levels, and support daily performance.

AI Analysis | Feedback

null

AI Analysis | Feedback

```html

Steve Fife, President & Chief Executive Officer

Steve Fife joined LifeVantage as Chief Financial Officer in 2017 and transitioned to President and Chief Executive Officer in 2020 or 2021. Before joining LifeVantage, he served as Chief Financial Officer and Chief Operating Officer at Evidera, Inc., a private equity-sponsored professional services firm. He also held the role of Chief Financial Officer for several publicly traded companies, including Active Power, Inc. and LECG. Additionally, he held senior financial positions at Gilead Sciences, Amkor Technologies, and JDS Uniphase. Steve Fife is an inactive Certified Public Accountant. He is slated to retire in April 2026 after nine years with LifeVantage.

Carl Aure, Chief Financial Officer

Carl Aure was appointed Chief Financial Officer of LifeVantage in October 2021. He brings over 24 years of finance and accounting experience, with more than 15 years in the direct selling industry. Prior to LifeVantage, he was the Chief Accounting Officer for New Age, Inc., a social selling company. He joined New Age in 2018 as Senior Vice President, Corporate Controller, following its acquisition of Morinda Holdings, Inc., where he had held various finance and accounting roles from 2005 to 2018. Earlier in his career, Mr. Aure spent eight years at KPMG, LLP, most recently as a Senior Manager. He is a Certified Public Accountant.

Kristen Cunningham, Chief Sales Officer

Kristen Cunningham has served as Chief Sales Officer of LifeVantage since June 2022, following her tenure as Interim Chief Sales Officer and other sales leadership positions within the company since November 2020. Before joining LifeVantage, she was the Director of Business Development and held other sales leadership roles at Shaklee Corporation from August 2011 to October 2020. From 2006 to 2011, Ms. Cunningham worked in various capacities in Distributor Support and Sales at NuSkin Enterprises.

Michelle Oborn, Chief People Officer

Michelle Oborn has been the Chief People Officer at LifeVantage since August 2022. She has been a key leader in the company's human resources department since 2009 and also directs LifeVantage Legacy, the company's non-profit organization. Before her time at LifeVantage, Ms. Oborn was the Human Resources Manager at Zrii International, a direct selling wellness company. From 2005 to 2008, she worked as a litigation and employment paralegal at Wrona Law Offices.

Alissa Neufeld, General Counsel

Alissa Neufeld was appointed General Counsel and Corporate Secretary of LifeVantage in March 2021. Before joining LifeVantage, she served as Chief Compliance Officer, Deputy General Counsel, and Assistant Corporate Secretary for Nature's Sunshine Products, Inc. from January 2017 to March 2021. Prior to that, Ms. Neufeld was Associate General Counsel to 1-800 Contacts, Inc. from April 2014 to January 2016.

```

AI Analysis | Feedback

LifeVantage Corporation (LFVN) faces several key risks inherent to its business model and the highly regulated industry in which it operates.

  1. Regulatory Scrutiny of Multi-Level Marketing (MLM) Business Model and Pyramid Scheme Allegations

    LifeVantage operates through a network of independent distributors, a multi-level marketing (MLM) model that has consistently drawn regulatory scrutiny and allegations of being an illegal pyramid scheme. The company has faced class-action lawsuits alleging that its compensation structure disproportionately emphasizes recruitment over actual product sales, leading to financial losses for many distributors. Although LifeVantage settled a class-action lawsuit in 2020 for $1.8 million while denying wrongdoing, the underlying concerns about the sustainability and legality of such models remain. A fundamental risk is the ability to retain existing independent distributors and attract new ones, as non-compliance by distributors with legal requirements or company policies can also harm the business.

  2. Product Claims, Regulatory Compliance, and Product Liability

    As a seller of nutrigenomic activators, dietary supplements, and other health-related products, LifeVantage is subject to strict government regulations, particularly from the U.S. Food and Drug Administration (FDA). The FDA regulates dietary supplements differently from conventional foods and drugs, and companies are prohibited from marketing products that are adulterated or misbranded. LifeVantage has previously received warning letters from the FDA concerning illegal health claims, including allegations of making unauthorized cancer treatment claims for its Protandim products. Additionally, the company faces inherent risks of product liability claims and potential product recalls, as evidenced by a voluntary recall of its Protandim dietary supplement in 2012 due to possible metal fragments from a third-party supplier.

  3. Intense Competition and Challenges in Customer/Distributor Retention and Revenue Growth

    LifeVantage operates in a highly competitive global market for dietary supplements and personal care products. The company faces challenges in distinguishing its products, such as the MindBody GLP-1 System, from numerous competitors, many of which offer similar products at potentially lower prices. Recent financial results indicate disappointing performance, with sales declines and forecasts projecting near-zero or even negative organic growth. Furthermore, LifeVantage has experienced declines in active customers and consultants, indicating difficulties in retaining its base, which is critical for a direct-selling company.

AI Analysis | Feedback

The rise of direct-to-consumer (DTC) brands and sophisticated influencer marketing models, enabled by advanced e-commerce platforms and digital advertising, presents a clear emerging threat. These alternative distribution models allow new and existing companies to market and sell health and wellness products directly to consumers with lower overhead and often greater convenience, thereby challenging the effectiveness and appeal of traditional multi-level marketing (MLM) distribution networks like the one utilized by LifeVantage. This ongoing shift can erode the pool of potential independent distributors and customers for MLM companies, making it increasingly difficult for them to compete effectively on distribution reach, customer acquisition costs, and pricing.

AI Analysis | Feedback

The addressable markets for LifeVantage Corporation's main products and services are sized globally unless otherwise specified. Here are the estimated market sizes for LifeVantage's key product categories: * **Nutrigenomic Activators:** The global nutrigenomics market size was accounted at approximately USD 613.01 million in 2025. North America held the largest share of this market in 2024. * **Dietary Supplements:** The global dietary supplements market size was estimated at USD 209.52 billion in 2025. Asia Pacific led the market with a 42.0% share in 2025. * **Nootropics:** The global nootropic supplement market size was valued at USD 5.71 billion in 2025. North America is a leading region in this market. * **Probiotics (Pre- and Pro-biotics):** The global probiotics market size was estimated at approximately USD 113.97 billion in 2025. Asia Pacific dominated the probiotics market with a 39.1% share in 2025. * **Weight Management:** The global weight management market size is calculated at USD 176.67 billion in 2025. North America is a leading region in the weight management market. * **Skin Care Products:** The global skin care products market size was valued at USD 172.7 billion in 2025. Asia Pacific dominated the skin care market with a 51.46% share in 2025. * **Hair Care Products:** The global hair care market size was valued at USD 113.93 billion in 2025. Europe dominated the hair care market with a 36.67% share in 2025. * **Bath and Body Products:** The global bath and shower products market size was valued at USD 52.10 billion in 2024. Asia-Pacific dominated this market with a 38.73% revenue share in 2024. * **Targeted Relief Products:** The global topical pain relief market size was valued at USD 11.0 billion in 2024. North America currently dominates this market, holding over 35.0% share in 2024.

AI Analysis | Feedback

Expected Revenue Growth Drivers for LifeVantage (LFVN) over the Next 2-3 Years

LifeVantage Corporation (LFVN) is expected to drive future revenue growth through several key initiatives over the next two to three years:

  1. LoveBiome Acquisition and Integration: The strategic acquisition and ongoing integration of LoveBiome are anticipated to be a significant revenue driver. This move positions LifeVantage at the intersection of natural GLP-1 activation and microbiome health markets, contributing to product diversification and growth. The LoveBiome product line contributed $4.1 million in revenue in the second quarter of fiscal 2026, and its integration is seen as a source of positive momentum for the company's fiscal 2026 outlook.
  2. Launch of New Products: LifeVantage plans to drive revenue through the introduction of new products, particularly from the integrated LoveBiome portfolio. Recent examples include the launch of AXIO X and Phytopower B in the second quarter of fiscal 2026, which are expected to boost engagement, consultant growth, and further diversify the product offerings.
  3. Enhanced E-commerce Capabilities through Shopify Partnership: A partnership with Shopify is underway to deliver enhanced e-commerce capabilities. This initiative aims to improve the company's online sales channels and overall customer experience, which can lead to increased direct-to-consumer revenue.
  4. Stabilization and Strategic Response in the GLP-1 Market: Despite facing increased competition from pharmaceutical GLP-1 drugs, LifeVantage is "redoubling efforts to stabilize" its MindBody GLP-1 system business. The company is actively evaluating options to respond to the changing competitive landscape, indicating a continued focus on maintaining and potentially growing revenue from this product line.

AI Analysis | Feedback

Share Repurchases

  • LifeVantage authorized a new share repurchase program of up to US$60 million of common stock in January 2026, effective through December 31, 2027.
  • Under a previous program announced in November 2017, the company repurchased 5,068,960 shares for US$43.27 million, completing 37.65% of the authorized amount.
  • The company extended its stock repurchase program in June 2023 until December 31, 2026.

Share Issuance

  • Information regarding significant share issuances by LifeVantage Corporation over the last 3-5 years is not readily available.

Inbound Investments

  • No information on large inbound investments made in LifeVantage by third-parties, such as strategic partners or private equity firms, is readily available within the specified timeframe.

Outbound Investments

  • LifeVantage announced the acquisition of LoveBiome, a direct sales company focused on microbiome care and wellness solutions, in September 2025, with the transaction closing in October 2025.
  • The acquisition aims to expand LifeVantage's consultant network in key markets like the US, Taiwan, and Europe, and to broaden its product portfolio in gut and microbiome health.
  • The financial terms of the LoveBiome acquisition were not disclosed.

Capital Expenditures

  • Capital expenditures were reported as $1.53 million for the first six months of fiscal year 2026.
  • Historical capital expenditures were $3.07 million in 2023 and $2.25 million in 2024.
  • Projected capital expenditures are $2 million for fiscal year 2026 and 2027, and $3 million for fiscal years 2028 through 2030, generally representing 1% of revenue.

Better Bets vs. Lifevantage (LFVN)

Peer Outperformance in Packaged Foods & Meats

LFVN has outperformed 72% of its 46 Packaged Foods & Meats peers over 5Y. Packaged Foods & Meats ranks 10th of 12 industries in Consumer Staples by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Packaged Foods & Meats constituents that LFVN has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
24%
of 51 industry peers · -50.2% return
3Y
72%
of 50 industry peers · -3.7% return
5Y
72%
of 46 industry peers · -4.7% return
No Packaged Foods & Meats peer with a comparable growth profile has beaten LFVN by more than 20pp over 5Y.
Median price return by industry across the Consumer Staples sector, ranked by 5Y. Packaged Foods & Meats is LFVN's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Food Distributors 8 3.4%32.9%59.1% CHEF 280% · USFD 215% · ANDE 132%
Consumer Staples Merchandise Retail 12 4.3%39.2%50.8% NGVC 170% · VLGEA 136% · WMT 122%
Tobacco 6 -15.4%15.8%48.9% PM 135% · MO 101% · TPB 75%
Food Retail 6 -13.0%66.4%32.1% CASY 280% · SFM 227% · KR 40%
Soft Drinks & Non-alcoholic Beverages 12 -3.8%-12.6%13.3% COKE 412% · BRFH 205% · CCHGY 113%
Brewers 3 -13.4%-27.3%2.9% BUD 41% · TAP 3% · SAM -68%
Agricultural Products & Services 11 -2.5%-1.3%-13.7% BG 74% · ADM 57% · INGR 37%
Household Products 19 4.2%-4.0%-24.6% IPAR 83% · ACU 70% · CL 31%
Personal Care Products 4 -5.8%-25.0%-26.2% ELF 236% · PG 15% · EL -67%
Packaged Foods & Meats ← 47 -18.5%-27.1%-31.7% MAMA 540% · LWAY 379% · SENEA 308%
Distillers & Vintners 5 -45.5%-59.1%-72.8% STZ -32% · BF-B -57% · MGPI -73%
Drug Retail 3 -38.8%-83.3%-92.3% HITI -66% · PETS -92% · SCNX -99%
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

LFVNHLFNUSUSNAMEDNATRMedian
NameLifevant.HerbalifeNu Skin .Usana He.Medifast Natures . 
Mkt Price6.3612.434.8514.0412.1814.2112.30
Mkt Cap0.11.30.20.30.10.30.2
Rev LTM1835,2011,375913317492703
Op Inc LTM64927041-202935
FCF LTM7322111641813
FCF 3Y Avg92175942191830
CFO LTM10384512892728
CFO 3Y Avg1131410155252841

Growth & Margins

LFVNHLFNUSUSNAMEDNATRMedian
NameLifevant.HerbalifeNu Skin .Usana He.Medifast Natures . 
Rev Chg LTM-20.1%5.5%-15.4%1.6%-34.0%6.8%-6.9%
Rev Chg 3Y Avg-4.0%1.1%-12.3%-1.1%-38.5%4.4%-2.6%
Rev Chg Q-23.1%5.4%-17.1%-5.3%-27.6%1.9%-11.2%
QoQ Delta Rev Chg LTM-6.5%1.3%-4.6%-1.4%-8.4%0.5%-3.0%
Op Inc Chg LTM-50.0%0.7%23.3%-26.2%-4,105.3%44.6%-12.8%
Op Inc Chg 3Y Avg44.4%9.7%-0.1%-24.0%-1,428.0%23.5%4.8%
Op Mgn LTM3.3%9.5%5.1%4.5%-6.2%6.0%4.8%
Op Mgn 3Y Avg3.6%8.5%3.6%6.8%-0.5%5.1%4.4%
QoQ Delta Op Mgn LTM-0.0%-0.2%-0.5%-0.8%-1.5%0.2%-0.4%
CFO/Rev LTM5.6%7.4%3.7%3.0%2.8%5.6%4.6%
CFO/Rev 3Y Avg5.6%6.2%6.0%6.2%3.8%6.0%6.0%
FCF/Rev LTM3.7%6.2%0.8%1.7%1.3%3.7%2.7%
FCF/Rev 3Y Avg4.4%4.3%3.4%4.7%2.6%4.0%4.1%

Valuation

LFVNHLFNUSUSNAMEDNATRMedian
NameLifevant.HerbalifeNu Skin .Usana He.Medifast Natures . 
Mkt Cap0.11.30.20.30.10.30.2
P/S0.40.20.20.30.40.50.4
P/Op Inc13.02.63.46.3-7.08.64.8
P/EBIT13.03.2-22.188.0-7.08.86.0
P/E15.67.9-1.1-11.4-5.314.03.4
P/CFO7.73.44.69.415.49.38.5
Total Yield9.3%12.6%-86.9%-8.8%-18.8%7.1%-0.8%
Dividend Yield3.0%0.0%4.9%0.0%0.1%0.0%0.1%
FCF Yield 3Y Avg9.2%19.3%13.2%6.6%8.2%6.0%8.7%
D/E0.11.71.10.00.20.10.2
Net D/E-0.11.40.3-0.6-1.0-0.2-0.2

Returns

LFVNHLFNUSUSNAMEDNATRMedian
NameLifevant.HerbalifeNu Skin .Usana He.Medifast Natures . 
1M Rtn-1.2%0.1%-5.4%-36.5%23.9%-29.5%-3.3%
3M Rtn-18.7%3.9%-15.2%-23.3%-2.8%-33.2%-17.0%
6M Rtn38.9%-36.3%-41.5%-34.8%15.7%-48.7%-35.5%
12M Rtn-50.2%27.1%-58.7%-56.0%-13.2%-15.7%-32.9%
3Y Rtn-3.7%-17.2%-77.5%-78.2%-85.3%-15.5%-47.4%
1M Excs Rtn-2.7%-3.8%-9.8%-40.4%19.2%-33.7%-6.8%
3M Excs Rtn-20.5%2.2%-16.9%-25.0%-4.5%-35.0%-18.7%
6M Excs Rtn26.8%-48.4%-53.6%-46.9%3.6%-60.8%-47.6%
12M Excs Rtn-70.3%12.1%-77.6%-75.3%-33.6%-34.8%-52.6%
3Y Excs Rtn-22.8%-95.3%-150.7%-151.7%-159.1%-86.1%-123.0%

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Protandim® product line95104120136150
LifeVantage® product line5616   
TrueScience® product line4956492323
AXIO® product line1513   
Other65444847
PhysIQ™ product line54   
Petandim® product line22   
Total229200213206220


Price Behavior

Price Behavior
Market Price$6.36 
Market Cap ($ Bil)0.1 
First Trading Date10/05/2004 
Distance from 52W High-51.9% 
   50 Days200 Days
DMA Price$6.42$5.91
DMA Trenddowndown
Distance from DMA-1.1%7.5%
 3M1YR
Volatility79.8%76.0%
Downside Capture148.59194.60
Upside Capture38.7871.96
Correlation (SPY)-11.1%12.4%
LFVN Betas & Captures as of 7/31/2026

 1M2M3M6M1Y3Y
Beta0.63-1.20-0.050.570.790.81
Up Beta-0.39-7.61-5.54-1.86-0.580.59
Down Beta0.76-2.55-1.630.250.521.18
Up Capture110%34%290%179%70%44%
Bmk +ve Days11223567138427
Stock +ve Days10213565124393
Down Capture65%149%153%130%147%91%
Bmk -ve Days11212859114326
Stock -ve Days10202657122348

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with LFVN
LFVN-51.5%75.7%-0.62-
Sector ETF (XLP)8.0%14.4%0.314.8%
Equity (SPY)20.1%12.8%1.1612.5%
Gold (GLD)30.9%29.0%0.92-2.0%
Commodities (DBC)39.9%20.3%1.54-4.0%
Real Estate (VNQ)9.9%13.7%0.448.8%
Bitcoin (BTCUSD)-30.1%43.7%-0.7014.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with LFVN
LFVN0.3%65.6%0.28-
Sector ETF (XLP)5.9%13.7%0.219.4%
Equity (SPY)13.1%17.2%0.5919.5%
Gold (GLD)19.7%18.7%0.852.2%
Commodities (DBC)11.5%19.6%0.463.3%
Real Estate (VNQ)2.0%18.9%0.0012.6%
Bitcoin (BTCUSD)9.6%52.7%0.3712.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with LFVN
LFVN-6.0%61.8%0.16-
Sector ETF (XLP)7.3%14.9%0.3517.7%
Equity (SPY)15.2%17.9%0.7225.4%
Gold (GLD)12.2%16.3%0.612.7%
Commodities (DBC)7.3%18.0%0.339.5%
Real Estate (VNQ)5.0%20.7%0.2020.5%
Bitcoin (BTCUSD)63.4%66.1%1.039.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date8142026
Short Interest: Shares Quantity1.2 Mil
Short Interest: % Change Since 7312026-4.4%
Average Daily Volume0.1 Mil
Days-to-Cover Short Interest21.2 days
Basic Shares Quantity12.5 Mil
Short % of Basic Shares9.7%

Earnings Returns History

Updated 8/31/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/27/2026-1.5%  
5/6/2026-16.3%-12.2%67.2%
2/4/2026-16.8%-8.3%-11.2%
11/4/20254.4%-6.0%-5.1%
9/4/2025-10.0%-12.6%-29.3%
5/6/2025-6.6%1.3%3.8%
2/5/2025-16.5%-14.9%-32.1%
10/29/2024-0.4%11.2%10.9%
...
SUMMARY STATS   
# Positive91211
# Negative161213
Median Positive6.9%10.1%17.6%
Median Negative-7.8%-11.3%-6.4%
Max Positive23.9%45.8%67.2%
Max Negative-21.7%-32.7%-32.1%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/27/2026-1.5%  
5/6/2026-16.3%-12.2%67.2%
2/4/2026-16.8%-8.3%-11.2%
11/4/20254.4%-6.0%-5.1%
9/4/2025-10.0%-12.6%-29.3%
5/6/2025-6.6%1.3%3.8%
2/5/2025-16.5%-14.9%-32.1%
10/29/2024-0.4%11.2%10.9%
8/28/2024-11.8%2.2%47.9%
5/2/20247.5%11.3%30.0%
1/30/2024-8.9%3.8%17.6%
11/9/2023-21.7%-32.7%-6.4%
8/28/202323.9%45.8%34.6%
5/4/202322.4%38.5%58.1%
2/2/20230.8%-3.9%-2.5%
11/2/20220.5%0.5%1.9%
8/23/2022-6.6%-10.5%-11.7%
5/3/20228.1%-0.2%3.6%
2/1/2022-18.5%-27.5%-12.8%
11/4/2021-1.9%6.9%-5.0%
8/19/20215.5%13.0%-1.6%
4/29/2021-6.8%-12.8%-8.6%
2/2/2021-3.0%9.1%-0.6%
11/3/2020-5.0%-3.7%-3.1%
8/18/20206.9%12.6%0.3%
SUMMARY STATS   
# Positive91211
# Negative161213
Median Positive6.9%10.1%17.6%
Median Negative-7.8%-11.3%-6.4%
Max Positive23.9%45.8%67.2%
Max Negative-21.7%-32.7%-32.1%

SEC Filings

Expand for More
Report DateFiling DateFiling
06/30/202608/27/202610-K
03/31/202605/06/202610-Q
12/31/202502/04/202610-Q
09/30/202511/04/202510-Q
06/30/202509/04/202510-K
03/31/202505/06/202510-Q
12/31/202402/05/202510-Q
09/30/202410/29/202410-Q
06/30/202408/28/202410-K
03/31/202405/02/202410-Q
12/31/202301/30/202410-Q
09/30/202311/09/202310-Q
06/30/202308/28/202310-K
03/31/202305/04/202310-Q
12/31/202202/02/202310-Q
09/30/202211/02/202210-Q
Collapse to Preview
Report DateFiling DateFiling
06/30/202608/27/202610-K
03/31/202605/06/202610-Q
12/31/202502/04/202610-Q
09/30/202511/04/202510-Q
06/30/202509/04/202510-K
03/31/202505/06/202510-Q
12/31/202402/05/202510-Q
09/30/202410/29/202410-Q
06/30/202408/28/202410-K
03/31/202405/02/202410-Q
12/31/202301/30/202410-Q
09/30/202311/09/202310-Q
06/30/202308/28/202310-K
03/31/202305/04/202310-Q
12/31/202202/02/202310-Q
09/30/202211/02/202210-Q
06/30/202208/23/202210-K
03/31/202205/03/202210-Q
12/31/202102/01/202210-Q
09/30/202111/04/202110-Q
06/30/202108/19/202110-K
03/31/202104/29/202110-Q
12/31/202002/02/202110-Q
09/30/202011/03/202010-Q
06/30/202008/18/202010-K
03/31/202005/05/202010-Q
12/31/201901/28/202010-Q
09/30/201910/30/201910-Q

Insider Activity

Updated 8/10/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Lewis, Darwin DirectBuy61720268.607056,0591,179,818Form
2Beindorff, Michael A TrustSell60520268.5510,00085,459355,723Form
3Lewis, Darwin DirectBuy31820265.231,0555,518714,224Form
4Dayton, Judd DirectBuy30220264.5310,50047,565364,026Form
5Dayton, Judd DirectBuy30220264.6318,09783,789323,447Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Lewis, Darwin DirectBuy61720268.607056,0591,179,818Form
2Beindorff, Michael A TrustSell60520268.5510,00085,459355,723Form
3Lewis, Darwin DirectBuy31820265.231,0555,518714,224Form
4Dayton, Judd DirectBuy30220264.5310,50047,565364,026Form
5Dayton, Judd DirectBuy30220264.6318,09783,789323,447Form
6Dayton, Judd DirectBuy30220264.584,60021,068237,070Form
7Lewis, Darwin DirectBuy21120265.223,95520,651707,569Form
8Lewis, Darwin DirectBuy121720256.548055,265860,343Form
9Beindorff, Michael A TrustSell112120256.4212,60780,934281,226Form
10Beindorff, Michael A DirectSell111020257.331,0007,330259,401Form
11Beindorff, Michael A TrustSell111020256.9235,000242,252390,463Form
12Lewis, Darwin DirectBuy918202510.854504,8821,271,793Form
13Beindorff, Michael A DirectSell911202511.444,12547,190261,496Form
14Beindorff, Michael A Spouse as Custodian for Minor ChildrenSell911202511.352002,2701,430Form
Core Cache Last Updated: 8/30/2026